Form 4 Filing for Harrington Robert Arthur

Robert Arthur Harrington, a director at Cytokinetics Inc. (CYTK), acquired 195 shares of Common Stock on October 16, 2026, under a director's equity in lieu of cash retainer program. The shares were acquired at a price of $63.92 per share. Following this transaction, Harrington holds a total of 22,127 shares. The filing was signed by John Faurescu, acting as attorney-in-fact for Harrington, on October 20, 2026.